Johnson & Johnson posts mixed results, narrows full-year guidance
Johnson & Johnson (NYSE:JNJ) reported mixed financial results for the first quarter of 2024, with adjusted earnings per share (EPS) slightly surpassing analyst expectations, while revenue fell marginally short of estimates. The healthcare giant posted an adjusted EPS of $2.71, which was $0.07 higher than the consensus estimate of $2.64. However, quarterly revenue was a hair\’s breadth away from consensus, coming in at $21.38 billion against the expected $21.4 billion.